 "AstraZeneca Q2 loss widens to Rs 27.96 crore")
The company has posted a net loss of Rs 1.22 crore in the July-September quarter period of the last fiscal.
AstraZeneca's total income from operation during the quarter under review was at Rs 114.67 against Rs 115.66 crore in the second quarter of the last fiscal, the company said in a filing to the BSE stock exchange.
Also Read
The company said that the result was not comparable as AstraZeneca group companies had acquired the global diabetic business of Bristol Myers Squibb Company.
Consequent to the acquisition, it had entered into a consignment sale agreement with Bristol Myers Squibb India for a transition period from February 1, 2014, to May 31, 2014, post which the company is directly selling these products.
Shares of AstraZeneca today closed at Rs 912.15 on the BSE, up 4.85 per cent from previous closing.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%